CYTORA is a clinical stage stem cell company developing a new class of medicines based on
a novel and transformative patented platform stem cell technology.
Harnessing the Power of hOMSC
The Ultra Potent Neural Crest Stem Cells.
A patented platform based on the discovery of human oral mucosa (hOMSC) stem cells which are unique and superior to other known kinds of stem cells.
OUR TECHNOLOGY
Clinical observation of wound healing in the mouth led to the discovery of hOMSC:
Rapid wound
healing compared
to other tissues.
Wound healing by regeneration as in fetus
(no scar tissue).
Regeneration
unaffected by
aging.
Wound healing is
negligibly affected
by diabetes.
hOMSC-based proprietary platform technology for
“off-the-shelf” products aimed at treating chronic wounds, neurodegenerative diseases and autoimmune disorders with a strong medical need.
human Oral Mucosa Stem Cells:
• Potent and safe neural crest stem cell population.
• Offer an allogeneic off-the-shelf product.
• Have a readily accessible source – the adult
oral mucosa.
• Have a dual mechanism of action: cell replacement and paracrine trophic effect.
Robust cGMP production line, production capabilities of one batch of Master Cell Bank sufficient to treat
thousands of patients.
UNDER CLINICAL DEVELOPMENT
Diabetic Wound
Healing
Central & Autonomic
Nervous System
hOMSC200 for Diabetic
Foot Ulcers (DFU)
hOMSC300 for Multiple System Atrophy (MSA) patients
LEADING TEAM
Highly experienced and execution-oriented management team Clear Go-To-Market strategy.
Prof. Sandu Pitaru
Jacob Zankel
Dr. Yona Geffen
Dr. Nissim Darvish
CO-FOUNDER, CSO,
VP R&D & CLIN AFFAIRS
CO-FOUNDER,
COO
CEO
CHAIRMAN
World Key Opinion Leaders (KOL’s), expert scientific advisors.
Leading clinical experts in their respective fields.